CARsgen makes history as China approves world's first CAR-T therapy for solid tumors
China's drug regulator approved satricabtagene autoleucel for Claudin18.2-positive gastric cancer after at least two prior therapies.
TL;DR
- On June 22, 2026, China's NMPA approved CARsgen's satricabtagene autoleucel for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction cancer.
- The labeled population is patients who have already received at least two prior lines of therapy. The company calls it the first approved CAR-T for a solid tumor.
- Company-reported Phase 2 figures were a median progression-free survival of 3.25 months versus 1.77 months on physician's choice. How widely the product will be used outside China is still open.
China's National Medical Products Administration approved satricabtagene autoleucel (satri-cel) on June 22, 2026, CARsgen said in a Hong Kong exchange filing the same day. The indication is Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. Fierce Pharma reported the decision as the first approval of a CAR-T therapy aimed at a solid tumor. [1, 2] [1] [2]
Satri-cel is an autologous CAR-T product directed at Claudin18.2. The exchange filing describes that protein as largely limited to differentiated gastric mucosal cells and highly expressed in gastric cancer. The company says it was the first to validate Claudin18.2 as a CAR-T target. Those statements are the sponsor's account of the target, not an independent laboratory finding. [1, 2] [1] [2]
Fierce Pharma reported Phase 2 results the company had presented at ASCO: median progression-free survival of 3.25 months with satri-cel versus 1.77 months with a physician's choice of chemotherapy, and median overall survival of 7.92 months versus 5.49 months. The exchange filing confirms the approval and the indication; it does not restate those survival figures. The comparison was with physician's choice, not with a single named regimen. [1] [1]
CARsgen said it is studying earlier-line and perioperative use, and that a Phase 1 study in pancreatic cancer is underway in China. Chief executive Zonghai Li told Fierce Pharma the company intends to seek use in more countries. The filing does not set a timetable for approvals outside China, so the geographic reach of the product remains open. [1, 2] [1] [2]
Why it matters
Approved CAR-T products have been concentrated in blood cancers. A regulated solid-tumor approval, even in one market and a late-line population, is a test of whether Claudin18.2 cell therapy can move beyond trials. The survival gains reported by the company are measured in months, and use beyond China is not yet an approved fact.
Editor's note
Manual catch-up of the June 22, 2026 approval. The 'first solid-tumor CAR-T' wording is the company's claim, also reported by Fierce Pharma. Survival figures are company-reported via Fierce Pharma and are not in the exchange filing. No treatment recommendation.